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Abstract
The ability of Plasmodium falciparum parasitized RBC (pRBC) to form rosettes with normal RBC is linked to the virulence of
the parasite and RBC polymorphisms that weaken rosetting confer protection against severe malaria. The adhesin PfEMP1
mediates the binding and specific antibodies prevent sequestration in the micro-vasculature, as seen in animal models. Here
we demonstrate that epitopes targeted by rosette disrupting antibodies converge in the loop of subdomain 3 (SD3) which
connects the h6 and h7 a-helices of PfEMP1-DBL1a. Both monoclonal antibodies and polyclonal IgG, that bound to epitopes
in the SD3-loop, stained the surface of pRBC, disrupted rosettes and blocked direct binding of recombinant NTS-DBL1a to
RBC. Depletion of polyclonal IgG raised to NTS-DBL1a on a SD3 loop-peptide removed the anti-rosetting activity.
Immunizations with recombinant subdomain 1 (SD1), subdomain 2 (SD2) or SD3 all generated antibodies reacting with the
pRBC-surface but only the sera of animals immunized with SD3 disrupted rosettes. SD3-sequences were found to segregate
phylogenetically into two groups (A/B). Group A included rosetting sequences that were associated with two cysteine-
residues present in the SD2-domain while group B included those with three or more cysteines. Our results suggest that the
SD3 loop of PfEMP1-DBL1a is an important target of anti-rosetting activity, clarifying the molecular basis of the
development of variant-specific rosette disrupting antibodies.
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Introduction
The ability of P. falciparum parasitized RBC (pRBC) to form
rosettes, clustering of uninfected erythrocytes around pRBC, is an
adhesion property that varies in-between isolates which has also
been found associated with the virulence of the parasite
[1,2,3,4,5,6,7]. Rosetting is linked to cerebral malaria [2,7] and
other forms of severe disease [6,8,9,10], and experimental models
suggest that rosetting enhances microvascular obstruction [11,12],
thought to be a key pathological process in severe malaria. The
importance of rosetting is underlined by the fact that host
erythrocyte polymorphisms that weaken rosetting (blood group O,
low levels of CR1, HbS) also confer protection against severe
malaria [1,2,3,5,13,14]. Blood group O is associated with a 66%
reduction in the odds of developing severe malaria compared with
the non-O blood groups [6,8,9,10]. The vaso-occlusive effects of
rosetting have consequently been suggested to be important for the
development of severe malaria [15].
Rosetting is mediated by the interaction of the parasite ligand
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)
with serum-proteins and receptors on the human RBC surface
[6,7]. PfEMP1 polypeptides share a common structure with an N-
Terminal Sequence (NTS) followed by tandemly arranged Duffy
Binding Like domains (DBL) and Cysteine-rich InterDomain
Regions (CIDR) [16,17,18]. The N-terminal NTS-DBL1a-do-
main is central for binding to host RBC [3,19,20,21] and
antibodies to this domain both disrupt rosettes in vitro and protect
against the sequestration of pRBC in vivo targeting PfEMP1
[22,23,24,25]. Previous work has also suggested NTS-DBL1a to
be involved in the binding to the erythrocyte- and endothelial
receptor heparan sulfate and the related glycosaminoglycan
heparin has been found to disrupt rosettes in vitro and dislodge
already sequestered pRBC into circulation in vivo [12,20,21].
PfEMP1-variants linked to rosetting are consequently important
vaccine candidates.
Recent studies have shown that rosette disrupting antibodies are
variant specific [26], but cross-reactivity can be observed in-
between parasites of the same rosetting-variant with antibodies
raised against whole NTS-DBL1a domains [27]. To identify and
characterize structures in the NTS-DBL1a-domain of PfEMP1
critical for rosetting we have here generated sets of recombinant
NTS-DBL1a-proteins that mediate rosetting and antibodies that
disrupt rosettes. The reactivity of rosette-inhibitory mAbs was
found to be predominantly localized in the loop of subdomain 3
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(SD3) which connects the h6 and h7 a-helices of NTS-DBL1a,
establishing this part as a key-region of PfEMP1 for induction of
anti-rosetting antibodies and link it to protection against severe
malaria. Analysis of polyclonal IgGs and human sera supported
the importance of antibodies targeting these epitopes also during
the acquisition of protective immunity. Our results therefore
suggest the SD3-loop of NTS-DBL1a to be an immunodominant
site of the PfEMP1 molecule important for protection against
rosetting.
Results
Antibodies to the NTS-DBL1a-domain Recognize
Epitopes on Live pRBCs
To identify and characterize the structures in PfEMP1 that
mediate rosetting we expressed three different species of NTS-
DBL1a of the rosetting parasites FCR3S1.2 (expressing the
PfEMP1 encoded by the IT4var60 gene), R29 (expressing the
PfEMP1 encoded by the IT4var9 gene) and PaloAlto varO as
histidine-tagged proteins in E.coli. The solubilized proteins were
purified to homogeneity and used for the production of sera in
goats, from which the polyclonal IgGs (pIgG) were purified. The
pIgGs reacted in ELISA with the corresponding recombinant
protein and labeled the surface of live RBC, infected with the
homologous parasites, in flow cytometry while IgG from non-
immunized goats (nIgG) did not (Fig. 1A and Fig. S2A). The
reactive antibodies specifically labeled the pRBC-surface and
disrupted the rosettes of the homologous parasite in a concentra-
tion dependent manner (Fig. 1B).
Three groups of BALB/c-mice were subsequently immunized
with recombinant NTS-DBL1a to produce mAbs; two groups with
the recombinant protein from IT4var60 and one group with the
protein from IT4var9 (Table 1). The reactivity of the mAbs, which
were positive with the fusion-proteins in ELISA, was assessed with
the live pRBC surface in flow cytometry and in rosette disruption
assays (Fig. 1C and D and Fig. S2B). A total of nine surface
reactive mAbs were generated after immunizations with NTS-
DBL1a of IT4var60 while immunization with NTS-DBL1a of
IT4var9 resulted in one surface reactive mAb. Two different
functional groups could be distinguished among the surface
reactive antibodies: eight out of ten (80%) were found to dose-
dependently disrupt rosettes while two of them did not have anti-
rosetting activity (mAbV2–4 and mAb V2–16) (Fig. 1D). The Fab-
fragments of the corresponding mAbs were also found to disrupt
rosettes while a control mAb did not (Fig. 1E).
Antibodies Prevent the Binding of NTS-DBL1a to the RBC
Surface
The proteins were assayed for binding to erythrocytes, in order
to study how the antibodies influenced the interaction of the
recombinant NTS-DBL1a-domain with RBC receptors. 10 mM of
recombinant NTS-DBL1a was incubated with human O+ RBCs
and the bound protein was visualized by flow cytometry.
Concentration-dependent binding of the proteins was detected
with the recombinant NTS-DBL1a of IT4var60 and NTS-DBL1a
of IT4var9 (Fig. S1). While pre-incubation of the homologous
recombinant protein with two of the mAbs specific for FCR3S1.2
(mAbV2–14.1, mAbV2–17.1) efficiently and dose-dependently
prevented binding, the effects of mAbV2–6 and mAbV2–3 were
less prominent (Fig. 1F) possibly due to differences in the fine
specificities for the NTS-DBL1a (see below). There was no
significant inhibition of binding with the non-rosette disruptive
antibodies mAbV2–4, mAbV2–16, mAbV2-c20 or mAbV2-c21
(Fig. 1F) suggesting that the binding of the recombinant NTS-
DBL1a to RBCs mimics parasite rosetting. The pIgGs also
blocked binding of recombinant NTS-DBL1a domains of
FCR3S1.2 and R29 to RBCs (Fig. 1G). No or minor effects on
binding were seen with control antibodies.
Rosetting Epitopes are Spatially Conserved
There is currently little data available as to what epitopes are
targeted by anti-rosetting antibodies. We therefore developed
a peptide array holding seven complete NTS-DBL1-sequences
(Table S1). It covered 400–450 aa per NTS-DBL1 domain with
<100 overlapping 15-mer peptides per sequence. Ten of the
mAbs that showed surface reactivity and four surface-negative
mAbs were studied for binding in the arrays. Four distinct sets of
linear epitopes as well as two overlapping conformational epitopes
were identified for the mAbs tested (Fig. 2). Three antibodies that
showed surface- and rosette disruption activity with pRBC of
FCR3S1.2 (mAbV2–3, mAbV2–6, mAbV2–11) bound to the 15-
mer peptide TCQGYNNSGYRIYCS of IT4var60, a sequence
localized within the loop that connects the two a-helices h6 and h7
of subdomain 3 (SD3) of DBL1a (Fig. 2A and D and Fig. S3A).
This sequence is also part of Homology Block HB12, which is
partially conserved among DBLa and DBLc domains as recently
described by Rask et al. [28].
Four biologically active mAbs (mAbV2–14.1, mAbV2–13,
mAbV2–7 and mAbV2–17.1) could not be mapped for reactivity
in the linear peptide array indicating that they possibly recognize
conformational epitopes (Fig. S3A). However three of them
(mAbV2–14.1, mAbV2–13 and mAbV2–7) were found to bind
a 19aa loop-sequence (KVKDTCQGYNNSGYRIYCS) when
loop-peptides longer than 15aa were studied for binding (Fig. 2A
and Fig. S4C). One mAb (mAbV2–17.1) was found to react with
epitopes related to the SD3-loop as demonstrated by antibody
competition experiments with pRBCs of FCR3S1.2 (Fig. S4A and
S4B). The data suggested that the epitopes recognized by
mAbsV2–17.1 and mAbV2–14.1 were not identical to that of
the inhibitory mAbs that bind to the linear SD3 epitopes, but
spatially related.
A third group of mAbs (mAbV2–4 and mAbV2–16) displayed
surface-reactivity but did not disrupt rosettes and could not be
mapped in the linear peptide array (Fig. S3A and S4C) suggesting
a different epitope-specificity as compared to the mAbs of the first
group.
A fourth subset of mAbs (mAbV2-c20 and mAbV2-c21) did not
react with the pRBC surface and did not confer any anti-rosetting
activity (Fig. 1D and Fig. S2B). mAb-c20 reacted in the microarray
with a stretch of residues localized on the a-helix h7 (KWINKKQ-
GEFNKQKK; Fig. 2C and E and Fig. S3A). It also showed
reactivity with the homologous recombinant protein as well as
cross-reactivity with two other NTS-DBL1a domains in ELISA
(Table 1). The epitope corresponds to the second part of the HB5,
as defined by Rask et al. [28], and is predicted to be surface-
exposed [29]: we therefore explored the possibility that it is
shielded by serum-proteins [30,31,32]. However, no binding of
mAbV2-c20 to the pRBC surface could be detected, indepen-
dently if the cells were stripped of serum proteins or studied
directly after in vitro culture in the presence of 10% human serum
(Fig. S2C) indicating that this epitope appears to be hidden. The
epitope of the second mAb in this group (mAbV2-c21), was
mapped to 15aa present in SD3-loop (YCSGDGEDCTNILKQ;
Fig. 2C and E and Fig. S3A). This stretch of amino-acids
corresponds to HB7 [28] and is fairly conserved and predicted to
be only partially surface exposed, which is confirmed by our data
(Fig. 2F).
PfEMP1 Rosetting Epitopes
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e50758
In a complementary set of experiments we studied mAbR29–
1.1, which binds to the surface of pRBC of R29, and two R29-
specific mAbs that did not (mAbR29-c3, mAbR29-c4). The
mAbR29–1.1epitope was mapped to the peptide RTYLKDNTI-
FIDLNC (Fig. S3B) that is localized in the SD3-loop of IT4var9-
DBL1a (Fig. 2B) indicating that the biologically active antibodies
described here target different variable regions within the same
loop structure. Similarly to mAbV2-c20, a surface negative mAb
(mAbR29-c3) bound to an amino acid stretch within h7 that is not
exposed at the pRBC surface (Fig. 2C). A third surface negative
mAb (mAbR29-c4) bound to the non-exposed, conserved
LARSFADIG motif present in subdomain 2 (SD2; Fig. 2C) and
was in addition cross-reactive with two other NTS-DBL1a
domains in ELISA.
SD3 of PfEMP1-DBL1a is the Target of Rosette-inhibitory
Antibodies
The importance of the SD3-loop as a target for biologically
active antibodies was established by the reactivity of the pIgG
generated towards the NTS-DBL1a-domain of IT4var60 as seen
in our peptide array. Among the 10 peptides showing the highest
Ab reactivity, only one represented the SD3 loop while the others
were derived from subdomain 1 (SD1; Fig. S3C). We therefore
absorbed the pIgG over NHS-activated agarose beads coupled to
the SD3-loop sequence and found that <70% of the anti-rosetting
effect was removed with a concurrent decrease of the ELISA
response towards the peptide, while the pRBC surface reactivity
remained unaltered (Fig. 3A). Absorption of the same pIgG on
a scrambled SD3-loop sequence (CTSSKDYIYVQGCNNR-
Figure 1. Characterization of antibodies towards the NTS-DBL1a-domain of rosette associated PfEMP1 molecules. A: Example of
surface reactivity of a pIgG (at 10 mg/ml) with FCR3S1.2 pRBC as detected by Alexa488-conjugated secondary antibody and visualized by flow
cytometry. pIgG and control nIgG are in blue and red respectively. B: Capacity of pIgG and sera to disrupt rosettes of the homologous parasite strain.
Antibodies were tested at different concentrations from 10 to 500 mg/ml. Presented are the rosetting levels relative to a control incubated with
100 mg/ml nIgG. Three different experiments were performed in duplicate and bars indicate 6 SD. C: Example of surface reactivity of a mAbs (at
20 mg/ml) towards the SD3-loop with FCR3S1.2 pRBCs as detected by Alexa488-conjugated secondary antibody and visualized by flow cytometry.
mAbV2–14.1 and control mAbSlyD are in blue and red respectively. D: Capacity of the mAbs to disrupt rosettes of the homologous parasite strain.
Antibodies were tested at different concentrations from 5 to 100 mg/ml. Presented are rosetting levels relative to a control incubated with 100 mg/ml
mAb SlyD. Three different experiments were performed in duplicate and bars indicate 6 SD. E: Capacity of Fab fragments and the corresponding
mAbs to disrupt rosettes of the homologous parasite strain. Antibodies were tested at different concentrations from 0.06 to 4 mM. Presented are
rosetting levels relative to a control incubated with 1 mMmAb SlyD. Three different experiments were performed in duplicate and bars indicate6 SD.
F: Inhibition of NTS-DBL1a-domain binding to RBC by mAbs. Recombinant NTS-DBL1a was incubated with different concentrations of mAbs and
thereafter assayed for its capacity to bind to human RBC. Binding was detected with anti-his mAb followed by Alexa488-conjugated secondary
antibody by flow cytometry. Binding is expressed as relative binding as compared to the control mAb SlyD. Three different experiments were
performed and bars indicate 6 SD. G: Inhibition of NTS-DBL1a-domain binding to RBC by homologous pIgG. Assays were carried out as described
under F. Three different experiments were performed and bars indicate 6 SD.
doi:10.1371/journal.pone.0050758.g001
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GYK) did not influence the rosette disruption activity and hence
confirmed the specificity and excluded possible unspecific absorp-
tion due to charge effects (Fig. 3A).
In order to investigate whether the SD3 of IT4var60
(FCR3S1.2) by itself could generate biologically active antibodies,
as does the complete NTS-DBL1a, we expressed the three distinct
subdomains (SD1, SD2 and SD3) of IT4var60 (FCR3S1.2var2) as
his-tagged fusion proteins and immunized rats. All the induced
Abs bound to the pRBC-surface but only SD3-specific Abs
disrupted rosettes to <50% (Fig. 3B and C) suggesting that the
SD3-loop of DBL1a is involved in the induction of anti-rosetting
responses.
Recognition of SD3-loop Peptides by Human Sera
Human sera diluted 1:1000 showed reactivity with the identified
SD3-peptides. The levels of IgG were measured by ELISA in sera
of 47 patients with uncomplicated malaria, 33 patients with severe
malaria, 40 malaria immune adults and 32 non-immune Swedish
controls (Fig. 4A). Anti-SD3-peptide antibody levels were high in
some children with severe malaria but these sera did not disrupt
rosettes while the IgG-levels were less pronounced in children with
mild disease (Fig. 4A). Mean IgG antibody-levels were still the
highest in sera of the immune adults for two of the SD3 peptides
but not for that of IT4var9, (p,0.0001). We also established that
the responses in the sera were co-correlated (R2 = 0.75, p,0.0001;
Fig. 4B).
Bioinformatics Analysis of NTS-DBL1a Sequences
Neighbor Joining distance trees were built based on amino acid
alignment of 144 SD1, SD2 or SD3 sequences (from NTS-h1
including the conserved LARSFADIG sequence, h2 to h5 or h6 to
h7 of NTS-DBL1a, respectively). The majority of PfEMP1-
DBL1a sequences from patients isolates available today lack the
sequence of the SD3 region. Therefore, only sequences of
laboratory parasites strains 3D7, IT4, Dd2 and HB3 were used
for the analysis. The sequences could be divided in two major
groups (Fig. 5 and Fig. S5A). This phylogenetic grouping was
found to be associated with the number of cysteine residues
present in SD2 of DBL1a, and resembles the previos grouping
obtained according to the SD2 sequence [33]. Of the 144 SD2-
sequences one had one cysteine residue, 34 sequences had 2, three
had 3, 101 had 4 and five had 5. The #2 cys (DBLa1) sequences
fell into one group (SD1 and SD3 group A) while sequences with
$3 cys fell into the second group (SD1 and SD3 group B).
Sequence signatures of the different groups are shown in Figure
S5B. Accordingly, <75% of sequences group into Group B, while
Figure 2. Identification a loop containing functionally important epitopes in subdomain 3 of the NTS-DBL1a-domain. A: Molecular
model of the NTS-DBL1a-domain of IT4var60, based on NTS-DBL1a-PAvarO crystal structure [29], showing the localization of epitopes targeted by
anti-rosetting antibodies (in red). B: Molecular model of the NTS-DBL1a-domain of IT4var9, based on NTS-DBL1a-PAvarO crystal structure [29],
showing the localization of epitopes targeted by anti-rosetting antibodies (in red). C: Molecular model of the NTS-DBL1a-domain of IT4var60, based
on NTS-DBL1a-PAvarO crystal structure [29], showing the localization of epitopes targeted by non surface reactive antibodies (in blue and green). D:
Representation of the molecular model of NTS-DBL1a-domain of IT4var60 with the three subdomains (SD) 1, 2 and 3 in black, brown and grey,
respectively. E: Two orthogonal views of the molecular model of NTS-DBL1a-domain of IT4var60 with surface exposed epitopes in red and non-
surface exposed epitopes in blue and green. F: Alignment of the SD3 sequences of three rosette-associated NTS-DBL1a-domains. The conserved
amino acid residues are in black. The recognition-sites of the mAbs mapped to this region are shown in color; epitopes in red are available on the
surface of pRBCs while the ones in blue and green are hidden. Arrows and dashed lines indicate cysteines and disulfide bridges, respectively.
doi:10.1371/journal.pone.0050758.g002
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<25% of sequences into Group A. Sequences of the rosetting
parasites IT4var60, IT4var9 and PAvarO studied herein, as well
as other sequences previously associated with severe parasite
phenotypes, all fall into SD1-SD3-group A.
Discussion
This study of erythrocyte-adhesive PfEMP1 polypeptides and
rosette-inhibitory antibodies employs multiple chemical- and
biological assays and presents two key findings: firstly, the
importance of the loop of SD3 of the NTS-DBL1a-domain,
a target of anti-rosetting activity and, secondly, the immunoge-
nicity of the SD3-loop in the induction of antibodies (Fig. S6).
These findings underline the importance of the SD3 domain in
molecular events linked to the rosetting phenomena.
We report the generation of a number of antibodies to distinct
NTS-DBL1a-domains that specifically bind to the surface of
pRBCs that disrupt rosettes or antibodies that only stain the
pRBC-surface. The specificities and the potencies of the mAbs
were confirmed by the fact that also Fab fragments specifically
reacted with the surface of the pRBCs and disrupted rosettes. The
epitopes recognized by the mAbs that were able to disrupt rosettes
were found to be localized in subdomain 3 and mainly within the
loop, despite displaying some heterogeneity in their fine specifi-
cities. Conformational epitopes recognized by additional function-
al antibodies were also localized closely to the SD3-loop since their
reactivities could be competed out with mAbs that bound to linear
epitopes within the loop. Furthermore we were able to reduce the
anti-rosetting activity of a pIgG directed to the whole NTS-
DBL1a domain by 70% by depleting the specific antibodies on
a SD3-loop peptide. Still, it is likely that several parts of the NTS-
DBL1a head-structure are involved in erythrocyte binding since
SD1 has previously been suggested to be involved in rosetting-
binding [29], and since our sera from the animals immunized with
SD3 could only partially disrupt rosettes. Recent reports argue
that SD3 of PfEMP1 VAR2CSA binds to CSA [34] but important
epitopes in VAR2CSA have also been found present outside of the
SD3-loop [35,36,37]. Whatever the case, the data presented here
Figure 3. Importance of the SD3 of PfEMP1-DBL1a in anti-rosetting response. A: Residual activity of pIgGIT4var60 after absorption on the
SD3-loop peptide of NTS-DBL1a of IT4var60 (KVKDTCQGYNNSGYRIYCS). ELISA plates were coated with 5 mg/ml of peptide and the absorption of the
pIgGs was verified by adding 10 mg/ml of the different pIgGs followed by ALP-conjugated secondary antibody. The peptide-absorbed/non-absorbed
pIgGs were tested for surface reactivity by flow cytometry at 10 mg/ml and for capacity to disrupt rosettes of the homologous parasite at 250 mg/ml.
As control pIgG were absorbed on the same peptide with scrambled sequence (CTSSKDYIYVQGCNNRGYK). All results are shown as relative reactivity
as compared to pIgG (set to 100%). Bars show the mean of six independent experiments 6 SD. B: pRBC surface reactivity of sera from rats on
FCR3S1.2/IT4var60 as detected by an Alexa488-conjugated secondary antibody and visualized by flow cytometry. The rats were immunized with
subdomain 1 (SD1; aa 1–119; brown), subdomain 2 (SD2; aa 120–272; light blue) or subdomain 3 (SD3; aa 273–393; dark blue) of IT4var60. Reactivity
of a pre-immune rat serum is shown in red. C: Rosette disruption activity of sera of rats immunized as described under A or with full length NTS
DBL1a (dilution 1:5). Presented are the rosetting levels relative to a control incubated with PBS. Six different experiments were performed in duplicate
and bars indicate SEM (Standard error of the mean). *** = p,0.001 as compared to pre-immune serum.
doi:10.1371/journal.pone.0050758.g003
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show that the loop located in SD3 of the DBL1a-domain is a highly
immunogenic part of PfEMP1 that is easily targeted by functional
Ab independently of the parasite strain and the animal species
used. In addition, the importance of the SD3 has recently been
pointed out in the P. vivax DBP (PvDBPII) DBL domain where the
SD3 is essential for PvDBPII binding to its receptor and mAbs
targeting residues in SD3 are able to inhibit this interaction [38].
Most of our mAbs reacted both with the pRBCs surface and
disrupted rosettes but two of them only bound to the pRBC
surface suggesting that mere binding of an antibody to PfEMP1
does not disrupt rosetting. It is also unlikely that our antibodies
sterically hinder the binding to the rosetting receptor at a distance
since the Fab fragments effectively inhibited rosetting. Taken
together with the pIgG peptide-absorption data and results from
immunizations with the three distinct subdomains (Fig. 3), this
argues that rosette-disruption is not due to distance-induced
conformational changes in PfEMP1 upon Ab binding but rather
receptor inhibition.
As reported for other pathogens and proteins [39,40,41]
antibodies commonly target immunodominant variable regions
located in proximity of conserved ligand binding-sites thus
inhibiting the interaction. Notably in the proximity of the SD3-
loop in h6, h7 and in the loop itself there are several basic residues
(arginine, histidine, lysine) that could be key for the interaction of
the NTS-DBL1a domain with the negatively charged erythrocyte
receptor heparan sulfate [20,29,42]. HB7 and HB12, which are
part of the SD3 loop, have also been suggested to carry motifs
specific for receptors adhesion [28]. Other studies also suggest that
receptor-binding sites are present in SD3 for DBL1a in the
binding to CR1 [43]. Yet different binding sites were identified for
the DBL domain of EBA-175-binding to Glycophorin A [44] and
for DBP-binding of P. vivax to DARC [45,46] but in the latter case
the SD3-loop was located in proximity of the RBC membrane
upon receptor binding suggesting a possible role in adhesion as
well.
The IgG levels of human sera to SD3-loop-peptides of
individuals living in areas where P. falciparum is endemic were
Figure 4. Individuals living in endemic areas acquire antibodies against SD3-loop sequences. A: IgGs levels in human sera (diluted
1:1000) against the NTS-DBL1a SD3-loop peptides from parasites IT4var60, IT4var9 and PAvarO as detected by ELISA. IgG levels were measured in 32
non-immune Swedish controls(C), 33 patients with severe malaria (SM), 47 patients with uncomplicated malaria (UM) and 40 immune adults (IM). B:
Correlation between patient-serum IgG reactivity as measured by ELISA with the SD3-loop peptides KVKDTCQGYNNSGYRIYCS (IT4var60),
DCTQTNLSHNQIFVDLDCP (PAvarO) and RTYLKDNTIFIDLNCPRCE (IT4var9). The sera were tested for reactivity towards the three distinct peptides in
ELISA (as described under B) and the correlation was tested using non-linear regression; R2 = 0.75, p,0.0001.
doi:10.1371/journal.pone.0050758.g004
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elevated, as compared to non-exposed adults. We found reactivity
with the three SD3-loop-peptides independently of the geo-
graphical origin of the sera for all the groups of patients
investigated. Unexpectedly, we measured higher antibody titers
in patients with severe disease as compared to patients with
uncomplicated malaria but the sera of the former group failed to
disrupt rosettes showing that the antibodies measured by ELISA
are not always functional. Although it is likely that only a fraction
of the IgG measured was protective, it is tempting to speculate that
human immunity is acquired in a stepwise manner where each
individual infection with rosetting-parasites boosts the antibody
response towards SD3-loop epitopes, protecting older children and
immune adults against severe malaria.
In a previous study, three rosetting parasite strains were found
to display variant specific surface epitopes and were grouped as
multiple serotypes [26]. Our data confirm this finding and suggests
that at least part of the molecular background to the serotypes is
found in variable sequences in the conserved location within the
SD3 of the DBL1a-domain. However, most sequence information
that is available to date covers only 80–150 aa tags produced with
primers located in the relatively conserved SD2 areas N-terminally
to the SD3-loop [47,48,49]. This part of the molecule is indeed
interesting since the number of cysteine residues present therein
has been found associated with the rosetting phenotype of the
parasite and the severity from malaria [48,49]. The bioinformatic
analysis presented here shows a similar clustering of the analyzed
sequences whether we consider just the DBL1a-tag (between
PoLV1 and PoLV4) of SD2 [48] or the SD3 part of DBL1a (from
a-helix h6 to a-helix h7) (Fig. 5) and suggests that determinants in
the SD3 sequence are also important and associated with disease
severity and rosetting. The analysis is corroborated by a previous
study by Rask et al. [28] where it is suggested that SD3 sequences
belonging to the DBLa1 class are well supported as a subgroup,
further subdividing it into two groups depending whether it is
followed by CIDRa or CIDRc. Further the authors demonstrated
the presence of a recombination hotspot between SD2 and SD3,
upstream of SD3-loop (HB7), hypothesizing independent function
of SD1+SD2 and SD3.
Development of variant specific anti-rosetting antibodies
appears to be the most common event in natural acquisition of
immunity to parasites [26], however cross-reactivity of anti-sera to
NTS-DBL1a in-between pRBC-surfaces of parasites was recently
reported by Ghumra et al [27]. The latter has been shown to be
extremely difficult to obtain in a laboratory and it is mainly
induced by immunizations with NTS-DBL1a from IgM-binding
parasites. Another possible rational design of a vaccine against
severe malaria could include minimal regions with biological
function. Our study now suggests a chimeric vaccine that could
include a number of SD3-loops derived from rosetting parasites
targeting different serological variants.
The data presented here support the notion that PfEMP1
sequences important for the acquisition of rosette-inhibitory
antibodies are localized within the SD3-loop of the DBL1a
domain. The efficacy of the Abs, the human serum-reactivity and
the ease with which we could induce biologically active Abs to
SD3 suggest this subdomain to be one of the major target for
protective antibodies that prevent the phenomenon of rosetting.
Materials and Methods
Ethics Statement
For the collection of human samples written informed consent
was obtained and the study was approved by Karolinska Institutets
Regional Ethical Review Board (permission 03/095) and the
Uganda National Council for Science and Technology (permission
MV 717). Animal immunizations were carried out commercially
by EMBL (Monterotondo, Italy) according to European Guide-
lines 86/609/EEC. Animal immunizations at Agrisera (Va¨nnas,
Sweden) were approved by the animal ethical committee at Umea˚
University (permissions A37–10 and A73–11) and followed the
Swedish Regulations (1988:534).
Parasite Cultures
P. falciparum laboratory strains were cultivated according to
standard methods [50], with modifications for patient isolates
[49,51]. The rosetting phenotype of FCR3S1.2 was maintained by
enrichment over a Ficoll-gradient [50], while enrichment on mAbs
was carried out as described for R29 and PAvarO [21].
Production of Recombinant Protein
NTS-DBL1 domains were PCR-amplified and cloned into the
pQE vector system (Qiagen) using specific primers (Table S2 for
all vectors and primers used in the study). While genomic DNA
was used for IT4var9 (R29var1) and SD3-IT4var60, E. coli codon-
optimized DNA was applied for PAvarO [21] and IT4var60
(FCR3S1.2var2) [52]. NTS-DBL1a-domains were expressed as C-
terminal 6x histidine-tagged recombinant proteins in the E. coli
strain BL21 DE3 (DslyD). Production of protein was induced at
OD600 = 0.6 with 0.1 mM IPTG. After 3 hours, the cells were
lysed by sonication. Inclusion bodies (IB) were sampled using high
speed centrifugation. The content of IB was solubilized in 6 M
Guanidine HCl, 50 mM Tris-HCl pH 8, 100 mM NaCl, 10 mM
EDTA pH 8, 10 mM DTT. All proteins were refolded by rapid
dilution using ice-cold 200 mM Tris-HCl pH 8, 10 mM EDTA
pH 8, 0.6 M L-arginine, 6.5 mM cysteamine, 3.7 mM cystamine.
Refolded NTS-DBL1a-domains were thereafter dialyzed and
concentrated using Amicon Ultracell centrifugal filter units
(Millipore). All proteins were purified by Immobilized Metal
Affinity Chromatography over Ni-NTA columns (Qiagen), eluted
with 500 mM imidazole and further purified to homogeneity using
size exclusion chromatography on a HiLoad 16/60 Superdex
75 pg column (GE-Healthcare). Correct folding was assessed by
circular dichroism.
Immunization of Animals and Generation of Monoclonal
and Polyclonal Antibodies
Mouse monoclonal antibodies were produced at EMBL Mono-
clonal Antibody Core Facility, Monterotondo, Italy (http://www.
embl.it/services/macf/index.html) as previously described [53].
Briefly, mice were immunized trice with 50 mg of recombinant
protein, at one month interval. Serum levels of antibodies were
measured in ELISA prior to fusion and a post fusion confirmatory
ELISA was carried out for selection of positive cell clones.
Monoclonality of the antibodies were either tested directly from
the obtained cell supernatants of antibody producing cell clones or
from purified from cell supernatants. After adjusting the pH to 7.4,
Figure 5. Phylogenetic tree of NTS-SD1 and SD3 sequences. The Neighbor Joining tree shows segregation of the NTS-SD1 (considered from
h1 to LARSFADIG) and SD3 (considered from h6 to h7) in two groups. Bootstrap support, after 1000 replicates, is only shown for the branches
separating different groups, black dots at nodes indicate bootstrap values above or equal to 50%. 1-cys sequences are colored in dark green, 2-cys in
green, 3-cys in pink, 4-cys in blue and 5-cys in yellow.
doi:10.1371/journal.pone.0050758.g005
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purification was performed over a ProteinG agarose column
(Pierce ThermoScientific, product#20399). Purified antibodies
were used in the experiments after being dialyzed against PBS and
subsequently concentrated. mAb SlyD, a mAb directed against an
E. coli heat-shock protein, was produced in the same way and used
as a control throughout the experiments.
Polyclonal antibodies were produced in goats and rats by Agrisera,
Umea˚, Sweden. Briefly, animals were immunized intramuscularly
with 200 mg of protein four times at one month intervals; for the first
immunization the protein was emulsified in Freund’s complete while
incomplete Freunds adjuvant was used for the remaining three; final
bleed was carried out two weeks after the last immunization. From
eachgoatapproximatelyone literof serumwasobtainedandtheIgGs
were purified over ProteinG columns.
ELISA Assay
To assess the reactivity of each mAb with recombinant protein,
ELISA assays were carried out as described [19]; plates were
coated with 50 ml of 2.5 mg/ml protein overnight in carbonate
buffer pH 9.6, subsequently blocked and thereafter incubated with
100 ml antibody containing solution in two different dilutions
(mAbs cell supernatants 1:20 and 1:40; purified mAbs at 5 and
2.5 mg/ml). Reactivity was visualized using an anti-mouse IgG-
ALP (dilution 1:1000; Sigma-Aldrich) conjugated antibody; mAb
SlyD was used as a control. For peptide ELISA the same protocol
was used with the following modifications: 5 mg/ml of peptide was
used for coating of plates, human serum was used at 1:1000
dilution followed by anti-human IgG-ALP conjugated antibody
(dilution1:1000, Sigma-Aldrich).
Analysis of Surface Reactivity of pRBC by Flow Cytometry
Trophozoite infected RBCs of <24–30 h p.i. were incubated
with the pIgGs (final concentration 10 mg/ml), mAbs (final
concentration 20 mg/ml) or rat sera (final dilution 1:10) for
30 min in a volume of 50 ml. Non-immune goat IgG, mAb SlyD
or pre-immune sera were used as controls in all experiments at the
same concentrations. After incubation with the primary antibody,
three washes with 200 ml PBS/2% FCS were performed followed
by 30 min incubation with species-specific anti-IgG antibody
coupled to ALEXA488 (dilution 1:100, Invitrogen) in volumes of
50 ml. All antibodies were diluted in PBS/2% FCS. For nuclear
staining, ethidium bromide was added at final concentration
2.5 mg/ml and pRBC were finally washed three times with 200 ml
and resuspended in 200 ml PBS with 2% FCS. The cell acquisition
was done using flow cytometry (FACSCalibur, BD Bioscience,
http://www.bd.com) where 5000 pRBC were counted. The
analysis was performed using FlowJo software. pRBCs incubated
with the fluorophore-labelled secondary antibody only were used
to define the non-reactive cell population; the percentage of
positive cells was thereafter determined in all samples.
Rosette Disruption Assay
To test the capacity of the pIgGs and mAbs to disrupt rosettes of
the different parasite clones/strains 45 ml aliquots of well
synchronized parasite culture 28–36 h p.i. were transferred to
a 96 well plate and carefully mixed (using a pipette tip with wide
opening, in order to avoid mechanical disruption of rosettes) with
5 ml of antibody solution. For pIgGs concentrations of 50, 100,
250 and 500 mg/ml, for mAbs concentrations of 10, 25, 50 and
100 mg/ml and for rat sera final dilution of 1:5, 1:10, 1:20 and
1:40 were applied; nIgG, mAb SlyD or pre-immune rat sera was
analyzed at the same concentrations as control. Incubation was
carried out for 60 min at RT, parasites were afterwards stained
with Acridine Orange and the rosetting rate was counted in
a fluorescent microscope. PRBC filling the RBC 1/3 or more were
considered as potentially rosetting and included in the counting;
counting of rosettes was carried out covering different areas of the
slide to cover for unevenly spread rosettes [50].
Erythrocyte Binding Assay
In order to analyze the capacity of the recombinant NTS-
DBL1a-domains to bind RBCs the proteins were incubated for
30 min at RT with RBCs (O+) from Swedish donors in 50 ml PBS.
After three washes with 200 ml PBS/2% FCS the complex was
incubated with 50 ml mAb anti-his antibody (dilution 1:200,
Qiagen) for 30 min at RT. This step was followed by three washes
with 200 ml PBS with 2% FCS and 30 min incubation with 50 ml
goat-anti-mouse IgG antibody ALEXA488-conjugated (dilution
1:100, Invitrogen). The complex was washed three times with
200 ml and re-suspended in 200 ml PBS with 2% FCS. The cell
acquisition was done using flow cytometry (FACSCalibur, BD
Bioscience, http://www.bd.com) where 100.000 RBCs were
counted. The analysis was performed using FlowJo software. For
the erythrocyte binding inhibition assay the same protocol was
followed with an additional 30 min pre-incubation of recombinant
NTS-DBL1a-domains with different dilutions of the mAbs and
pIgGs before incubation with RBCs.
Biotinylation of mAbs and Competition Assay
mAbs were biotinylated using the EZ-Link NHS-PEG Solid-
Phase Biotinylation Kit (Pierce ThermoScientific, product
#21440) according to manufacturer’s instructions. Analysis of
surface reactivity was carried out as described above with the
following modifications: after 30 min incubation with unlabelled
mAb (50 ug/ml in 50 ml), pRBC were washed and incubated with
biotinylated mAb (50 ug/ml in 50 ml); Streptavidin-FITC (50 ml,
dilution 1:300, Invitrogen) was added for surface staining.
pIgG Absorption
Peptides were conjugated to NHS activated agarose (Pierce
ThermoScientific, product #26197) according to manufacturer’s
instructions. Briefly 1 mg/ml (455 mM) of peptide in PBS was
mixed with dry resin for 1 hour at RT followed by 30 minutes
incubation in Tris pH 8. After re-equilibration of the resin in PBS,
1 ml of pIgG, at 1 mg/ml concentration, was added and
incubated overnight at 4uC. After elution the flow-through was
re-incubated for 2 hours at RT. The final flow-through was
collected, concentrated, and absorption verified by ELISA on the
corresponding peptide.
Peptide Array
Peptide microarrays were manufactured by JPT (JPT Peptide
Technologies, Germany) with each slide containing three
identical subarrays of <100 overlapping, 15aa long, peptides for
each of seven NTS-DBL1a-sequences from various parasite
laboratory strains and isolates (Table S1). Slides were incubated
for 16 hours at 4uC with 5 mg/ml, 250 ml volume, of the antibody
of interest in PBS buffer containing 3% of FCS and 0.5% Tween
(TPBS). After washing twice with TPBS and trice with distilled
water, slides were incubated with species-specific Cy5-conjugated
secondary antibody (Jackson ImmunoResearch). Following wash-
ing steps, slides were scanned at 635 nm using a GenePix 4000B
microarray scanner (Axon Instruments, CA, USA) and images
analyzed using GenePixPro 7.0 software in combination with the
GAL file provided by JPT. The mean fluorescence intensities
obtained from the foreground minus the local background were
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used to calculate the antibody responses; data presented here
correspond to the average of the three subarrays.
Protein Modeling
The 3D structures of NTS-DBL1aIT4var60, NTS-DBL1aIT4var9
and NTS-DBL1a-CIDR1cIT4var60 were modeled using the Phyre2
server [54]. The crystal structure of NTS-DBL1a PAvarO (PDB
accession code 2XUO) [29] was used as a template. Structural
visualizations and high-resolution images were generated using
PyMol (The PyMOL Molecular Graphics System, Version 1.3,
Schro¨dinger, LLC.).
Bioinformatic Analysis
Sequences of 3D7 (52 sequences), IT4 (36 sequences), Dd2 (26
sequences), HB3 (22 sequences) and other parasites (8 sequences)
were obtained from GenBank [55], varDB [56] and VarDom [28]
databases. The multiple sequence alignments were performed
using ClustalW with default parameters and unrooted [57].
Phylogenic trees were built using the Neighbour-Joining method
using Molecular Evolutionary Genetic Analysis 5 (MEGA5) [58].
Trees were edited and visualized using Dendroscope [59].
Statistical Analysis
All values are expressed as mean 6 SD. Comparisons between
different groups were made using Students unpaired t test or
Mann-Whitney test (for non-normally distribuited samples). Non-
linear regression was used to correlate serum-IgG levels.
Supporting Information
Figure S1 Binding of the recombinant NTS-DBL1a
domains to RBCs. Recombinant NTS-DBL1a was incubated
at 25, 50 and 100 mg/ml (green, blue and yellow respectively) with
RBCs in PBS. Binding was detected with anti-his mAbs, followed
by secondary antibody Alexa488-conjugated, by flow cytometry.
In red is shown the binding of a control his-tagged recombinant
protein (NTS-DBL1a of TM284S2).
(TIF)
Figure S2 Activity of antibodies towards the NTS-
DBL1a-domain of rosette associated PfEMP1 molecules.
A: Surface reactivity of 10 mg/ml pIgG/1:5 serum, followed by
secondary antibody Alexa488-conjugated, with pRBC of the
homologous parasite strain/clone as visualized by flow cytometry.
nIgG and anti-NTS-DBL1a pIgGs/anti SD3-serum are in red
and blue respectively. B: Surface reactivity of mAbs (at 20 mg/ml)
with homologous pRBC as detected by Alexa488-conjugated
secondary antibody and visualized by flow cytometry. mAbs and
control mAbSlyD are in blue and red respectively. C: Surface
reactivity of mAbV2-c20 (at 20 mg/ml), with homologous pRBC
as detected by Alexa488-conjugated secondary antibody and
visualized by flow cytometry, in presence (+) or absence (–) of
human serum proteins. pRBCs were stripped using sodium citrate
(5) to remove bound serum proteins (including immunoglobulins)
prior to mAb labeling. mAbV2-c20 and control mAbSlyD are in
blue and red respectively.
(PDF)
Figure S3 Results of peptide microarrays. A: Reactivity of
the different mAbs on the NTS-DBL1aIT4var60 microarray. The
graphs indicate the reactivity of the mAbs towards the 15-mers
peptide covering the NTS-DBL1aIT4var60 sequence (peptide
sequences on the y-axis N-terminal to C-terminal, bottom to
top). B: Reactivity of the different mAbs on the NTS-
DBL1aIT4var9 microarray. The graphs indicate the reactivity of
the mAbs towards the 15-mers peptide covering the NTS-
DBL1aIT4var9 sequence (peptide sequences on the y-axis N-
terminal to C-terminal, bottom to top). C: Reactivity of the pIgGs
to IT4var60/FCR3S1.2 on the NTS-DBL1a microarrays. The
graphs indicate the reactivity of the pIgG (black line) and nIgG
(blue line) towards the 15-mers peptide covering the homologous
NTS-DBL1a sequence (peptide sequences on the x-axis N-
terminal to C-terminal, left to right). The area corresponding to
the SD3-loop is highlighted in red.
(PDF)
Figure S4 Recognition of SD3-loop by mAbs. A: Surface
labeling competition. Residual surface reactivity of biotinylated (B)
mAbs after pre-incubation with unlabeled mAbs. pRBC were pre-
incubated with 50 mg/ml unlabeled mAbs and subsequently
incubated with 50 mg/ml of biotinylated mAbs. Surface reactivity
was detected with Streptavidin-FITC by flow cytometry. Results
are shown as residual reactivity relative to biotinylated mAb pre-
incubated with PBS. Three different experiments were performed
and bars indicate 6 SD. B: Surface reactivity of biotinylated
mAbs with pBRCs, after pre-incubation with unlabelled mAbs, as
described under A, visualized by flow cytometry. Plots are
representative of typical results showing different degrees of
inhibition. Red: mAb SlyD, blue: B-var2–14.1, green: residual
reactivity of B-V-14.1 after pre-incubation of pBRCs with mAb as
indicated in the figure. C: ELISA reactivity of the V2-mAbs
towards the SD3-loop peptide (KVKDTCQGYNNSGYRIYCS).
ELISA plates were coated with 5 mg/ml of peptide and the
reactivity of the mAbs was verified by adding 25 mg/ml of the
different mAbs followed by ALP-conjugated secondary antibody.
The vertical black bar is the threshold for positivity as calculated
by the background binding of mAb-SlyD+2SD.
(TIF)
Figure S5 Multiple sequence alignment of SD3 se-
quences. A: Multiple sequence alignment of SD3 sequences,
used to build the phylogenetic tree in Fig. 4, generated using
ClustalW. Sequences from helix 6 to helix 7 were aligned. Protein
IDs are indicated in the first column while Cys type in the last
column (Cys1, Cys2, Cys3, Cys4 or Cys5). 144 unique protein
sequences have been used for the alignment and two protein
sequences (PFDG_03037 and XP_001351079) have been re-
moved. B: Consensus sequence generated from the multiple
alignments for the two distinct groups as seen in Fig. 4. The first
line indicates the amino acid number, the second line indicates the
consensus sequence: aa shaded in black have .99% conservation
while aa in grey have .80% consensus. The third line is the motif
logo generated using WebLogo.
(PDF)
Figure S6 Relative localization of the SD3-loop. Cartoon
suggesting possible binding mode of antibodies to the SD3-loop of
NTS-DBL1a, maintaining the correct relative sizes of the domains
as compared to IgG. The cartoon shows a possible structure of
PfEMP1 with the molecular model of NTS-DBL1a-CIDR1c
domains in the N-terminus. The localization of the SD3-loop (red)
and an antibody (blue) are indicated.
(TIF)
Table S1 PfEMP1 sequences on the peptide microarray.
(DOC)
Table S2 PCR-primers and vectors used to generate
NTSDBL1a-expression constructs.
(DOC)
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